Results 61 to 70 of about 3,063 (143)

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis

Frontiers in Pharmacology, 2022
Objective: This review was performed to compare the efficacy and safety among hospitalized patients with COVID-19 who received baricitinib and those who received tocilizumab independently with placebo or the standard of care (SOC).Methods: Relevant ...
Jerin Jose Cherian, Madhavi Eerike, Bhavani Shankara Bagepally, Saibal Das, Saibal Das, Samiran Panda   +5 more
doaj   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis [PDF]

, 2022
INTRODUCTION: Indirect treatment comparison was used to compare approved doses of baricitinib and dupilumab for treating adult patients with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.
de Bruin-Weller, Marjolein, Raibouaa, Afaf, Serra-Baldrich, Esther, Capron, Jean-Philippe, Schuster, Christopher, Werfel, Thomas, Grond, Susanne, Universitat Autònoma de Barcelona, Barbarot, Sebastien, de Bruin-Weller, Marjolein S., Serra-Baldrich, E, Petto, Helmut   +11 more
core   +1 more source

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids

Rheumatology and Therapy, 2018
Introduction This study assessed if concomitant use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or corticosteroids altered the response or safety outcomes to baricitinib in rheumatoid arthritis (RA) patients.
Ronald van Vollenhoven, Cameron Helt, Vipin Arora, Jinglin Zhong, Ana Pinto Correia, Inma de la Torre, David Muram   +6 more
doaj   +1 more source

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

Arthritis Research & Therapy, 2021
Objective To compare the efficacy and safety of tofacitinib and baricitinib in patients with RA in a real-world setting. Methods A total of 242 patients with RA who were treated with tofacitinib (n = 161) or baricitinib (n = 81) were enrolled.
Naoki Iwamoto, Shuntaro Sato, Shota Kurushima, Toru Michitsuji, Shinya Nishihata, Momoko Okamoto, Yoshika Tsuji, Yushiro Endo, Toshimasa Shimizu, Remi Sumiyoshi, Takahisa Suzuki, Akitomo Okada, Tomohiro Koga, Shin-ya Kawashiri, Keita Fujikawa, Takashi Igawa, Toshiyuki Aramaki, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Akinari Mizokami, Tomoki Origuchi, Yukitaka Ueki, Katsumi Eguchi, Atsushi Kawakami   +24 more
doaj   +1 more source

A RETROSPECTIVE CASE CONTROL STUDY TO ASSESS THE EFFECTIVENESS OF BARICITINIB AMONG MODERATE TO SEVERE COVID-19 CASES; EXPERIENCE FROM A SOUTH INDIAN TERTIARY CARE CENTRE

International Journal of Infectious Diseases, 2023
Intro: Dysregulated inflammation plays a key role in the development of severe SARS-CoV-2 infection. One of the key cellular signaling pathway involved in the inflammatory response is JAK/STAT signaling. Among the hospitalized Covid patients with hypoxia
N.T. Kambhampati, D. Sathyapalan, M. Moni, G. Pillai M, R. Moosa   +4 more
doaj   +1 more source

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, British Society for Rheumatology Biologics Register in Rheumatoid Arthritis Contributors Group, Kimme L. Hyrich   +8 more
wiley   +1 more source

Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib

Dermatology and Therapy
Introduction Alopecia areata (AA) is an autoimmune disease associated with high rates of emotional and psychosocial distress. The analysis reported here describes the evolution of measures assessing health-related quality of life (HRQoL) and symptoms of ...
Brittany Craiglow, Yang Won Lee, Sergio Vañó-Galván, Alexander Egeberg, Yves Dutronc, Frederick Durand, Evangeline Pierce, Guanglei Yu, Yun-Fei Chen, Arash Mostaghimi   +9 more
doaj   +1 more source

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

Arthritis Research & Therapy, 2017
Background This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional ...
Michael Schiff, Tsutomu Takeuchi, Roy Fleischmann, Carol L. Gaich, Amy M. DeLozier, Douglas Schlichting, Wen-Ling Kuo, Ji-Eon Won, Tara Carmack, Terence Rooney, Patrick Durez, Saeed Shaikh, Rodolfo Pardo Hidalgo, Ronald van Vollenhoven, Cristiano A. F. Zerbini   +14 more
doaj   +1 more source

Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study

Life, 2023
Background. The aim of the study was to assess the effect of baricitinib on 28-day all-cause mortality and the progression of respiratory failure in patients needing transfer to the intensive care unit (ICU) with COVID-19 pneumonia treated with high-flow
Dušanka Obradović, Milica Popović, Maja Banjac, Jelena Bulajić, Vladimir Đurović, Ivana Urošević, Aleksandra Milovančev   +6 more
doaj   +1 more source